株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注射型ドラッグデリバリーの世界市場:医療機器のパイプライン評価

Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 372544
出版日 ページ情報 英文 613 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
注射型ドラッグデリバリーの世界市場:医療機器のパイプライン評価 Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2017
出版日: 2017年09月12日 ページ情報: 英文 613 Pages
概要

当レポートでは、世界の注射型ドラッグデリバリー (薬剤送達) の関連製品の市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 注射型ドラッグデリバリーの概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:分野別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • パイプライン製品:現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 注射型ドラッグデリバリーの企業:治験段階別のパイプライン製品
  • 注射型ドラッグデリバリー:治験段階別のパイプライン製品

第5章 注射型ドラッグデリバリー市場:企業・製品の概要

  • Aciont Inc.
  • Actavis Inc.
  • AdrenaCard, Inc.
  • Allergan, Inc.
  • Alsensa ApS
  • AMAG Pharmaceuticals, Inc.
  • Amgen Inc.
  • Antares Pharma, Inc.
  • Anterion Therapeutics, Inc. (Inactive)
  • Arnali, LLC
  • Artemes Technologies, Inc.
  • AstraZeneca Plc
  • Atanse, Inc.
  • AzureBio, S.L.
  • Becton, Dickinson and Company
  • Bespak Europe Ltd.
  • Biodel Inc.
  • BioMarin Pharmaceutical Inc.
  • BioRestorative Therapies, Inc.
  • Boston University
  • BTG Plc
  • Burke Pharmaceuticals, LLC
  • Callisyn Biomedical Inc
  • Cambridge Consultants Limited
  • Case Western Reserve University
  • Cincinnati Children's Hospital Medical Center
  • Clearside BioMedical, Inc.
  • Consort Medical plc
  • Credence MedSystems, Inc.
  • CrossCoat Medical LLC
  • Cytosial Biomedic, S.a.s.
  • DALI Medical Devices Ltd.
  • Delcath Systems, Inc.
  • DelSite, Inc. (Inactive)
  • Elcam Medical
  • EmboMedics
  • Emergent BioSolutions Inc.
  • Eveon SAS
  • Ghent University
  • Hannover Medical School
  • Indian Institute of Science
  • Inovio Pharmaceuticals, Inc.
  • LyoGo
  • Medicom Innovation Partner a/s
  • Meridian Medical Technologies, Inc.
  • Mertiva AB
  • Microchips Biotech, Inc.
  • Midatech Pharma Plc
  • Milestone Scientific Inc.
  • North Carolina State University
  • Ocelus
  • Oval Medical Technologies Limited
  • Particle Therapeutics Ltd
  • Pfizer Inc.
  • Portal Instruments, Inc.
  • pSivida Corp.
  • Ratio, Inc.
  • Recon Therapeutics, LLC
  • Replenish Inc
  • RepliCel Life Sciences, Inc.
  • RetinaPharma Technologies, Inc.
  • Rx Safes, Inc.
  • Scandinavian Health Ltd
  • Shire Plc
  • Spine Smith, LP
  • Sun Pharmaceutical Industries Limited
  • TCB medical devices
  • Teva Pharmaceutical Industries Ltd.
  • Texas Tech University
  • TheraKine Ltd. (Inactive)
  • Unilife Corporation
  • United Therapeutics Corporation
  • University College London
  • University of Auckland
  • University of Calgary
  • University of California, Irvine
  • University of California, San Diego
  • University of California, San Francisco
  • University of Delaware
  • University of Dundee
  • University of Florida
  • University of Missouri
  • University of Saskatchewan
  • University of Texas at Austin
  • Urodelia SA
  • Vanderbilt University

第6章 注射型ドラッグデリバリー市場:昨今の動向

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0448EPD

GlobalData's Medical Devices sector report, "Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2017" provides an overview of Injectable Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Injectable Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Injectable Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Injectable Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Injectable Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 13
  • 1.2 List of Figures 20

2 Introduction 21

  • 2.1 Injectable Drug Delivery Overview 21

3 Products under Development 22

  • 3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development 22
  • 3.2 Injectable Drug Delivery - Pipeline Products by Segment 23
  • 3.3 Injectable Drug Delivery - Pipeline Products by Territory 24
  • 3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path 25
  • 3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 26
  • 3.6 Injectable Drug Delivery - Ongoing Clinical Trials 27

4 Injectable Drug Delivery - Pipeline Products under Development by Companies 28

  • 4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 28
  • 4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development 32

5 Injectable Drug Delivery Companies and Product Overview 36

  • 5.1 Aciont Inc Company Overview 36
  • 5.2 Adamis Pharmaceuticals Corp Company Overview 38
  • 5.3 AdrenaCard, Inc. Company Overview 40
  • 5.4 Allergan Inc Company Overview 41
  • 5.5 Alsensa ApS Company Overview 42
  • 5.6 AMAG Pharmaceuticals Inc Company Overview 43
  • 5.7 Antares Pharma Inc Company Overview 44
  • 5.8 Anterion Therapeutics, Inc. (Inactive) Company Overview 48
  • 5.9 Arnali, LLC Company Overview 50
  • 5.10 Artemes Technologies, Inc. Company Overview 51
  • 5.11 Ascendis Pharma A/S Company Overview 52
  • 5.12 Ascil Proyectos SL Company Overview 55
  • 5.13 AstraZeneca Plc Company Overview 56
  • 5.14 Atanse, Inc. Company Overview 57
  • 5.15 AzureBio SL Company Overview 59
  • 5.16 Becton Dickinson and Co Company Overview 60
  • 5.17 Bespak Europe Ltd Company Overview 62
  • 5.18 BioCorRx Inc Company Overview 64
  • 5.19 BioMarin Pharmaceutical Inc Company Overview 65
  • 5.20 BioRestorative Therapies Inc Company Overview 66
  • 5.21 Bioxis Pharmaceuticals Company Overview 67
  • 5.22 Boston University Company Overview 68
  • 5.23 BTG Plc Company Overview 69
  • 5.24 Burke Pharmaceuticals LLC Company Overview 71
  • 5.25 Callisyn Biomedical Inc Company Overview 72
  • 5.26 Cambridge Consultants Ltd Company Overview 74
  • 5.27 Camurus AB Company Overview 75
  • 5.28 Case Western Reserve University Company Overview 78
  • 5.29 Cincinnati Children's Hospital Medical Center Company Overview 79
  • 5.30 Clearside BioMedical Inc Company Overview 80
  • 5.31 Consort Medical plc Company Overview 84
  • 5.32 CrossCoat Medical LLC Company Overview 86
  • 5.33 DALI Medical Devices Ltd. Company Overview 87
  • 5.34 Delcath Systems Inc Company Overview 91
  • 5.35 DelSite, Inc. (Inactive) Company Overview 95
  • 5.36 Elcam Medical Company Overview 96
  • 5.37 EmboMedics Company Overview 100
  • 5.38 Emergent BioSolutions Inc Company Overview 101
  • 5.39 Eveon SAS Company Overview 102
  • 5.40 Ferring Pharmaceuticals A/S Company Overview 104
  • 5.41 Ghent University Company Overview 105
  • 5.42 Hannover Medical School Company Overview 106
  • 5.43 Inovio Pharmaceuticals Inc Company Overview 107
  • 5.44 InVivo Therapeutics Corp Company Overview 109
  • 5.45 kaleo Inc Company Overview 110
  • 5.46 LyoGo Company Overview 111
  • 5.47 Medicom Innovation Partner a/s Company Overview 112
  • 5.48 Meridian Medical Technologies Inc Company Overview 113
  • 5.49 Mertiva AB Company Overview 114
  • 5.50 Micron Biomedical Inc Company Overview 115
  • 5.51 Midatech Pharma Plc Company Overview 116
  • 5.52 Milestone Scientific Inc Company Overview 117
  • 5.53 North Carolina State University Company Overview 120
  • 5.54 Ocelus Company Overview 121
  • 5.55 Particle Therapeutics Ltd Company Overview 122
  • 5.56 Pfizer Inc Company Overview 123
  • 5.57 Portal Instruments Inc Company Overview 124
  • 5.58 pSivida Corp Company Overview 125
  • 5.59 QuiO Technologies LLC Company Overview 132
  • 5.60 Radius Health Inc Company Overview 133
  • 5.61 Ratio Inc Company Overview 134
  • 5.62 Recon Therapeutics, LLC Company Overview 136
  • 5.63 Replenish Inc Company Overview 137
  • 5.64 RepliCel Life Sciences Inc Company Overview 138
  • 5.65 Rescitech Vision Pvt Ltd Company Overview 139
  • 5.66 RetinaPharma Technologies Inc Company Overview 140
  • 5.67 Roche Diagnostics International Ltd Company Overview 141
  • 5.68 Rx Safes Inc Company Overview 144
  • 5.69 Scandinavian Health Ltd Company Overview 145
  • 5.70 Sensile Medical AG Company Overview 146
  • 5.71 SMC Ltd Company Overview 149
  • 5.72 SpineSmith Holdings, LLC Company Overview 150
  • 5.73 Sun Pharma Advanced Research Company Ltd Company Overview 151
  • 5.74 TCB medical devices Company Overview 152
  • 5.75 Teva Pharmaceutical Industries Ltd Company Overview 153
  • 5.76 Texas Tech University Company Overview 155
  • 5.77 TheraKine Inc (Inactive) Company Overview 156
  • 5.78 Twin Star Medical Inc Company Overview 158
  • 5.79 Unilife Corporation Company Overview 159
  • 5.80 United Therapeutics Corp Company Overview 162
  • 5.81 University College London Company Overview 163
  • 5.82 University of Auckland Company Overview 164
  • 5.83 University of Calgary Company Overview 165
  • 5.84 University of California Irvine Company Overview 166
  • 5.85 University of California San Diego Company Overview 167
  • 5.86 University of California San Francisco Company Overview 169
  • 5.87 University of Delaware Company Overview 170
  • 5.88 University of Dundee Company Overview 171
  • 5.89 University of Florida Company Overview 172
  • 5.90 University of Missouri Company Overview 174
  • 5.91 University of Saskatchewan Company Overview 175
  • 5.92 University of Texas at Austin Company Overview 176
  • 5.93 Vanderbilt University Company Overview 178
  • 5.94 West Pharmaceutical Services Inc Company Overview 179
  • 5.95 Windgap Medical Inc Company Overview 180
  • 5.96 XERIS Pharmaceuticals Inc Company Overview 181
  • 5.97 Ypsomed Holding AG Company Overview 182

6 Injectable Drug Delivery- Recent Developments 183

  • 6.1 Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 183
  • 6.2 Sep 01, 2017: Kaleo Donates Thousands of EVZIO (naloxone HCl injection) Auto-injectors to Hurricane Harvey Relief Efforts 184
  • 6.3 Sep 01, 2017: Kaleo Donates Thousands of AUVI-Q (epinephrine injection, USP) Auto-injectors to Hurricane Harvey Relief Efforts 185
  • 6.4 Aug 30, 2017: Repatha Receives Approval for New 420mg Single-Dose Delivery Option in Japan 186
  • 6.5 Aug 29, 2017: Delcath Announces Medical University of Hannover in Germany Celebrates 100th CHEMOSAT Treatment 186
  • 6.6 Aug 28, 2017: Catalent Reports Fourth Quarter and Full Year 2017 Results 187
  • 6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 189
  • 6.8 Aug 21, 2017: Shire Director and Senior Management Changes 192
  • 6.9 Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 193
  • 6.10 Aug 18, 2017: District Court Issues Final Judgment - Retractable Technologies v. Becton, Dickinson 195
  • 6.11 Aug 17, 2017: Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen Auto-Injector 195
  • 6.12 Aug 17, 2017: Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability for Underpaying EpiPen Rebates 196
  • 6.13 Aug 16, 2017: Astrazeneca Non-executive Director Retirement 197
  • 6.14 Aug 15, 2017: Changes in Novo Nordisk Executive Management 197
  • 6.15 Aug 14, 2017: Milestone Scientific Provides Business Update for the Second Quarter of 2017 198
  • 6.16 Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 199
  • 6.17 Aug 09, 2017: Clearside Biomedical Announces Second Quarter 2017 Financial Results and Provides Corporate Update 199
  • 6.18 Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 201
  • 6.19 Aug 08, 2017: Milestone Scientific Announces First Patient Treated with CompuFlo Epidural Instrument at University of Miami Hospital 206
  • 6.20 Aug 08, 2017: Delcath Announces Second Quarter 2017 Financial Results 207
  • 6.21 Aug 08, 2017: Clearside Biomedical Announces Changes to its Board of Directors 209
  • 6.22 Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 209
  • 6.23 Aug 08, 2017: Antares Pharma Reports Second Quarter 2017 Operating And Financial Results 211
  • 6.24 Aug 07, 2017: Kaleo Announces AUVI-Q (epinephrine injection, USP) Charitable Donation Program for All Public Elementary Schools in the United States 212
  • 6.25 Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 214
  • 6.26 Aug 03, 2017: Executive Board Changes at Merck 216
  • 6.27 Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 216
  • 6.28 Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 220
  • 6.29 Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 221
  • 6.30 Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 225
  • 6.31 Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results 227
  • 6.32 Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 230
  • 6.33 Aug 01, 2017: MRI Interventions Reports 79% Revenue Increase and Record Treatments in Second Quarter 2017 234
  • 6.34 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 237
  • 6.35 Jul 31, 2017: Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences 244
  • 6.36 Jul 31, 2017: Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense 244
  • 6.37 Jul 27, 2017: U.S. FDA Grants Priority Review for an Epinephrine Auto-Injector in Development by Kaleo Specifically for Infants and Small Children 245
  • 6.38 Jul 27, 2017: AstraZeneca Announce H1 2017 Results 246
  • 6.39 Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results 253
  • 6.40 Jul 27, 2017: Dr. Reddy's Q1 FY18 Financial Results 254
  • 6.41 Jul 27, 2017: West Announces Second-Quarter 2017 Results 255
  • 6.42 Jul 27, 2017: United Therapeutics Reports Second Quarter 2017 Financial Results 257
  • 6.43 Jul 25, 2017: Vancouver's EVA Vein Care Now Offers New Varicose Vein Treatment 259
  • 6.44 Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio 260
  • 6.45 Jul 25, 2017: Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance 260
  • 6.46 Jul 24, 2017: Alisha A. Alaimo Appointed SVP of Biogen's US Therapeutic Operations 263
  • 6.47 Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 264
  • 6.48 Jul 21, 2017: Dr. Reddy's Laboratories: Update On US FDA Audit at API Cuernavaca Plant 264
  • 6.49 Jul 21, 2017: Merck Opens New Application Laboratory in Shanghai 264
  • 6.50 Jul 18, 2017: Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 265
  • 6.51 Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 266
  • 6.52 Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 266
  • 6.53 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 267
  • 6.54 Jul 11, 2017: Portal Instruments Appoints Wendy Dwyer as Chief Business Officer 269
  • 6.55 Jul 11, 2017: Milestone Scientific Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company 269
  • 6.56 Jul 11, 2017: MRI Interventions Announces Record Second Quarter ClearPoint System Procedures, And a 79% Year-Over-Year Revenue Increase 270
  • 6.57 Jul 10, 2017: Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs 271

7 Appendix 608

  • 7.1 Methodology 608
  • 7.2 About GlobalData 611
  • 7.3 Contact Us 611
  • 7.4 Disclaimer 611

List of Tables

1.1 List of Tables

  • Table 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
  • Table 2: Injectable Drug Delivery - Pipeline Products by Segment 25
  • Table 3: Injectable Drug Delivery - Pipeline Products by Territory 26
  • Table 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
  • Table 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Table 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
  • Table 7: Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 30
  • Table 8: Injectable Drug Delivery - Pipeline Products by Stage of Development 34
  • Table 9: Aciont Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 10: DSP - Visulex - Product Status 38
  • Table 11: DSP - Visulex - Product Description 38
  • Table 12: Visulex-I - Product Status 39
  • Table 13: Visulex-I - Product Description 39
  • Table 14: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 15: Symjepi - Product Status 40
  • Table 16: Symjepi - Product Description 40
  • Table 17: Symjepi - Junior Version - Product Status 41
  • Table 18: Symjepi - Junior Version - Product Description 41
  • Table 19: AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 20: Adrenacard Auto-Injector - Product Status 42
  • Table 21: Adrenacard Auto-Injector - Product Description 42
  • Table 22: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 23: NOVADUR Intravitreal Implant - Product Status 43
  • Table 24: NOVADUR Intravitreal Implant - Product Description 43
  • Table 25: Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 26: SQJCT - Product Status 44
  • Table 27: SQJCT - Product Description 44
  • Table 28: AMAG Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 29: Makena Auto-Injector - Product Status 45
  • Table 30: Makena Auto-Injector - Product Description 45
  • Table 31: Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 32: QuickShot Auto Injector - Product Status 46
  • Table 33: QuickShot Auto Injector - Product Description 47
  • Table 34: QuickShot Testosterone (QST) - Product Status 47
  • Table 35: QuickShot Testosterone (QST) - Product Description 47
  • Table 36: Teva Pen 1 - Product Status 48
  • Table 37: Teva Pen 1 - Product Description 48
  • Table 38: Vibex EPI - Product Status 48
  • Table 39: Vibex EPI - Product Description 48
  • Table 40: Vibex Qs - Makena - Product Status 49
  • Table 41: Vibex Qs - Makena - Product Description 49
  • Table 42: Vibex QS M - Product Status 49
  • Table 43: Vibex QS M - Product Description 49
  • Table 44: Anterion Therapeutics, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 45: Ambulin - Product Status 50
  • Table 46: Ambulin - Product Description 50
  • Table 47: Choless - Product Status 51
  • Table 48: Choless - Product Description 51
  • Table 49: Complimens - Product Status 51
  • Table 50: Complimens - Product Description 51
  • Table 51: Arnali, LLC Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 52: Arnali Drug Delivery Device - Product Status 52
  • Table 53: Arnali Drug Delivery Device - Product Description 52
  • Table 54: Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 55: Artemes Magnetic Injection System - Product Status 53
  • Table 56: Artemes Magnetic Injection System - Product Description 53
  • Table 57: Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 58: TransCon hGH Auto-Injector - Product Status 54
  • Table 59: TransCon hGH Auto-Injector - Product Description 54
  • Table 60: Ascendis Pharma A/S - Ongoing Clinical Trials Overview 55
  • Table 61: TransCon hGH Auto-Injector - Long-term Extension of HEIGHT Study 56
  • Table 62: Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 63: Prefilled Device - Product Status 57
  • Table 64: Prefilled Device - Product Description 57
  • Table 65: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 66: Second Generation Bydureon Pen - Product Status 58
  • Table 67: Second Generation Bydureon Pen - Product Description 58
  • Table 68: Atanse, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 69: CEDSYS - Product Status 59
  • Table 70: CEDSYS - Product Description 59
  • Table 71: Intracerebral Microinjection Instrument - Product Status 60
  • Table 72: Intracerebral Microinjection Instrument - Product Description 60
  • Table 73: AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 74: Injectable Needle - Product Status 61
  • Table 75: Injectable Needle - Product Description 61
  • Table 76: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 77: BD Intevia Disposable Autoinjector - Product Status 62
  • Table 78: BD Intevia Disposable Autoinjector - Product Description 62
  • Table 79: BD Libertas Wearable Injector - Product Status 63
  • Table 80: BD Libertas Wearable Injector - Product Description 63
  • Table 81: T2 Patch Wearable Injector - Product Status 63
  • Table 82: T2 Patch Wearable Injector - Product Description 63
  • Table 83: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 84: INJ650 ASI Auto-Injector - Product Status 64
  • Table 85: INJ650 ASI Auto-Injector - Product Description 64
  • Table 86: INJ700 Lila Mix Injector - Product Status 65
  • Table 87: INJ700 Lila Mix Injector - Product Description 65
  • Table 88: BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 89: Naltrexone Implant - Product Status 66
  • Table 90: Naltrexone Implant - Product Description 66
  • Table 91: BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 92: Pegvaliase Pre-filled Syringe - Product Status 67
  • Table 93: Pegvaliase Pre-filled Syringe - Product Description 67
  • Table 94: BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 95: Curved Needle Device - Product Status 68
  • Table 96: Curved Needle Device - Product Description 68
  • Table 97: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 98: Vaccine Delivery Device - Product Status 69
  • Table 99: Vaccine Delivery Device - Product Description 69
  • Table 100: Boston University Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 101: Polymeric Drug Delivery System - Product Status 70
  • Table 102: Polymeric Drug Delivery System - Product Description 70
  • Table 103: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 104: Varithena - Product Status 71
  • Table 105: Varithena - Product Description 72
  • Table 106: Varithena - Aesthetic Leg Veins - Product Status 72
  • Table 107: Varithena - Aesthetic Leg Veins - Product Description 72
  • Table 108: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 109: BURKE201 Needle Injection Pen - Product Status 73
  • Table 110: BURKE201 Needle Injection Pen - Product Description 73
  • Table 111: Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 112: 8Spheres Embolic Microspheres - Product Status 74
  • Table 113: 8Spheres Embolic Microspheres - Product Description 74
  • Table 114: TACEspheres Drug Eluting Embolic Microspheres - Product Status 75
  • Table 115: TACEspheres Drug Eluting Embolic Microspheres - Product Description 75
  • Table 116: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 117: Flexi-ject - Product Status 76
  • Table 118: Flexi-ject - Product Description 76
  • Table 119: Camurus AB Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 120: FluidCrystal Injection Depot - Setmelanotide - Product Status 77
  • Table 121: FluidCrystal Injection Depot - Setmelanotide - Product Description 77
  • Table 122: Camurus AB - Ongoing Clinical Trials Overview 78
  • Table 123: FluidCrystal Injection Depot - Setmelanotide - Phase Ia Study of Weekly Setmelanotide in Genetic Obesity 79
  • Table 124: Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 125: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Status 80
  • Table 126: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Description 80
  • Table 127: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 128: Pre-Filled Syringe With Flush - Product Status 81
  • Table 129: Pre-Filled Syringe With Flush - Product Description 81
  • Table 130: Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 131: SCS Microinjector - Product Status 82
  • Table 132: SCS Microinjector - Product Description 82
  • Table 133: Clearside BioMedical Inc - Ongoing Clinical Trials Overview 83
  • Table 134: SCS Microinjector - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-infectious Uveitis 84
  • Table 135: SCS Microinjector - A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion: SAPPHIRE 84
  • Table 136: SCS Microinjector - Multi-center, Non-interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated with Non-infectious Uveitis 84
  • Table 137: SCS Microinjector - Phase I/II Study of CLS-1002 for Wet Age-related Macular Degeneration (AMD) 85
  • Table 138: Consort Medical plc Pipeline Products & Ongoing Clinical Trials Overview 86
  • Table 139: INJ200 Autoinjector - Product Status 86
  • Table 140: INJ200 Autoinjector - Product Description 86
  • Table 141: SYR075 - Product Status 87
  • Table 142: SYR075 - Product Description 87
  • Table 143: CrossCoat Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 88
  • Table 144: CCM-D - Product Status 88
  • Table 145: CCM-D - Product Description 88
  • Table 146: DALI Medical Devices Ltd. Pipeline Products & Ongoing Clinical Trials Overview 89
  • Table 147: SAN-DV - Product Status 89
  • Table 148: SAN-DV - Product Description 89
  • Table 149: SAN-DV Pro - Product Status 90
  • Table 150: SAN-DV Pro - Product Description 90
  • Table 151: SAN-L - Product Status 90
  • Table 152: SAN-L - Product Description 91
  • Table 153: SAN-Light Premium Safety Needle - Product Status 91
  • Table 154: SAN-Light Premium Safety Needle - Product Description 91
  • Table 155: SAN-P - Product Status 92
  • Table 156: SAN-P - Product Description 92
  • Table 157: Delcath Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 93
  • Table 158: Hepatic CHEMOSAT Delivery System - Product Status 93
  • Table 159: Hepatic CHEMOSAT Delivery System - Product Description 93
  • Table 160: Delcath Systems Inc - Ongoing Clinical Trials Overview 94

List of Figures

1.2 List of Figures

  • Figure 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
  • Figure 2: Injectable Drug Delivery - Pipeline Products by Segment 25
  • Figure 3: Injectable Drug Delivery - Pipeline Products by Territory 26
  • Figure 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
  • Figure 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Figure 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
Back to Top